Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
Noviello S, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM, Dryden M, Balser B, Scaramucci A, Torres A, Huang DB. Noviello S, et al. Among authors: corey gr. J Med Microbiol. 2020 Apr;69(4):625-630. doi: 10.1099/jmm.0.001177. J Med Microbiol. 2020. PMID: 32195649 Free article. Clinical Trial.
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG Jr, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR; FAST Investigator Group. Stryjewski ME, et al. Among authors: corey gr. Clin Infect Dis. 2005 Jun 1;40(11):1601-7. doi: 10.1086/429914. Epub 2005 Apr 28. Clin Infect Dis. 2005. PMID: 15889357 Clinical Trial.
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG Jr, Morganroth J, Barriere SL, Kitt MM, Corey GR; FAST 2 Investigator Group. Stryjewski ME, et al. Among authors: corey gr. Antimicrob Agents Chemother. 2006 Mar;50(3):862-7. doi: 10.1128/AAC.50.3.862-867.2006. Antimicrob Agents Chemother. 2006. PMID: 16495243 Free PMC article. Clinical Trial.
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Stryjewski ME, et al. Among authors: corey gr. Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896. Clin Infect Dis. 2008. PMID: 18444791 Clinical Trial.
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial.
Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG Jr. Bae IG, et al. Among authors: corey gr. J Clin Microbiol. 2009 Dec;47(12):3952-7. doi: 10.1128/JCM.01643-09. Epub 2009 Oct 21. J Clin Microbiol. 2009. PMID: 19846653 Free PMC article. Clinical Trial.
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Corey GR, et al. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827. Clin Infect Dis. 2010. PMID: 20695801 Clinical Trial.
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group. Rubinstein E, et al. Among authors: corey gr. Clin Infect Dis. 2011 Jan 1;52(1):31-40. doi: 10.1093/cid/ciq031. Clin Infect Dis. 2011. PMID: 21148517 Free PMC article. Clinical Trial.
265 results